Targeted therapies for rare lung diseases
AboutUs
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
TherapeuticFocus
Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.
News
<
November 28, 2022
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »May 24, 2021
Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »October 16, 2020
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »April 27, 2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »May 15, 2017
Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Read more »September 3, 2014
Will Little-Known Company’s Inhaled Candidate Take Down InterMune-Roche’s Pirfenidone?
Read more »August 5, 2014
Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Read more »May 13, 2014
Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Read more »April 21, 2014
Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Read more »>